ibrutinib,rituximab
abbvie,janssen
[]
two takeaways from this slide:
1) pts w tp53mut do much better w btki 2) although data are cut off for the ki-67 low group, seems only ~26% of patients had ki-67&gt;30%. i wonder whether ibr noninferiority to asct will hold in aggressive mcl (a v i rather than this slide)? #ash22 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer